Thus, dysregulation of cholesterol homeostasis using drugs such as lovastatin, in combination with lapatinib, shows an enhanced therapeutic effect over lapatinib alone in HER2 BC patients (revised in [216]). This evidence concerns the gene ERBB2 and breast cancer.